Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance
- 7 February 2021
- journal article
- research article
- Published by Elsevier BV in International Journal of Antimicrobial Agents
- Vol. 57 (4), 106299
- https://doi.org/10.1016/j.ijantimicag.2021.106299
Abstract
No abstract availableKeywords
Funding Information
- Merck
- Meso Scale Diagnostics
- Pfizer (NCT02387372)
- Merck Sharp and Dohme
This publication has 32 references indexed in Scilit:
- Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trialThe Lancet Infectious Diseases, 2019
- Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa InfectionsAntimicrobial Agents and Chemotherapy, 2017
- Augmented renal clearance in non–critically ill abdominal and trauma surgery patients is an underestimated phenomenonThe Journal of Trauma and Acute Care Surgery, 2016
- Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam StudyAntimicrobial Agents and Chemotherapy, 2016
- Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)The Lancet, 2015
- Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)Clinical Infectious Diseases, 2015
- Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)International Journal of Antimicrobial Agents, 2014
- Augmented Renal Clearance in the ICUCritical Care Medicine, 2014
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)Antimicrobial Agents and Chemotherapy, 2013
- Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance PhenotypesAntimicrobial Agents and Chemotherapy, 2011